Truist Securities Maintains Hold on Zimmer Biomet Holdings, Maintains $117 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Zimmer Biomet Holdings with a price target of $117.
September 05, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has reiterated its Hold rating for Zimmer Biomet Holdings, keeping the price target at $117. This suggests a neutral outlook on the stock.
The Hold rating and unchanged price target indicate that the analyst does not expect significant short-term movement in Zimmer Biomet's stock price. This suggests a neutral stance, reflecting a balance between potential risks and rewards.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100